EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Activating mutations in the Epidermal Growth Factor Receptor (EGFR) gene are key drivers in non-small-cell lung cancer (NSCLC).
• EGFR tyrosine kinase inhibitors (TKIs) have emerged as a critical targeted therapy for NSCLC patients with specific EGFR mutations.

Purpose of the Study:

• To review the evolution and efficacy of first-line EGFR tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC).
• To evaluate both monotherapy and combination strategies involving EGFR TKIs to enhance treatment outcomes and delay resistance.

Main Methods:

• Comprehensive literature review of studies on EGFR TKIs in first-line NSCLC treatment.
• Analysis of data from first-generation to proposed fourth-generation EGFR TKIs.
• Examination of combination therapies including chemotherapy, anti-angiogenic drugs, and immune checkpoint inhibitors.

Main Results:

• EGFR TKI monotherapy demonstrates significant benefit for NSCLC patients with EGFR mutations in the first-line setting.
• Combination strategies involving EGFR TKIs have shown promise in delaying the onset of treatment resistance.
• Evidence supports the use of EGFR TKIs across multiple generations, with ongoing research into novel combinations.

Conclusions:

• First-line EGFR TKIs represent a cornerstone of targeted therapy for EGFR-mutated NSCLC.
• Combination approaches hold potential for improving long-term efficacy and overcoming resistance mechanisms.
• Future directions involve optimizing combination strategies with chemotherapy, anti-angiogenic agents, and immunotherapy.